Size | Price | Stock | Qty |
---|---|---|---|
500mg |
|
||
2g |
|
||
5g |
|
||
10g |
|
||
25g |
|
||
50g |
|
||
Other Sizes |
|
Purity: ≥98%
Sarcosine [also called N-methylglycine, Sarcosinic acid, Methylaminoacetic acid, Methylglycine] is a competitive inhibitor of the type I glycine transporter (GlyT1) and an N-methyl-D-aspartate receptor (NMDAR) co-agonist. Sarcosine is a GlyR agonist in addition to being a GlyT1 inhibitor and NMDAR co-agonist, but it is less potent than glycine as a GlyR agonist and is not a full agonist. The viability of the sarcosine-treated cells is significantly reduced. Sarcosine has weak anticonvulsant properties.
ln Vivo |
The electroconvulsive threshold is markedly elevated by scosine (400–800 mg/kg; ip) [2].
|
---|---|
Animal Protocol |
Animal/Disease Models: Albino Swiss mouse body weight (25-30 g)[2]
Doses: 100 mg/kg, 200 mg/kg, 400 mg/kg, 800 mg/kg Route of Administration: intraperitoneal (ip) injection Experimental Results: in mice MEST In trials, epilepsy thresholds were elevated at doses of 400 mg/kg and 800 mg/kg. |
References |
[1]. Katarzyna Socała, et al. Effects of sarcosine, a glycine transporter type 1 inhibitor, in two mouse seizure models. Pharmacol Rep. Mar-Apr 2010;62(2):392-7.
[2]. Mei-Yi Lee, et al. Effects of sarcosine and N, N-dimethylglycine on NMDA receptor-mediated excitatory field potentials. J Biomed Sci. 2017; 24: 18. |
Molecular Formula |
C3H7NO2
|
|
---|---|---|
Molecular Weight |
89.09
|
|
CAS # |
107-97-1
|
|
Related CAS # |
Sarcosine-15N;Sarcosine-d3;118685-91-9
|
|
SMILES |
O([H])C(C([H])([H])N([H])C([H])([H])[H])=O
|
|
Synonyms |
|
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: 100 mg/mL (1122.46 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
 (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 11.2246 mL | 56.1230 mL | 112.2460 mL | |
5 mM | 2.2449 mL | 11.2246 mL | 22.4492 mL | |
10 mM | 1.1225 mL | 5.6123 mL | 11.2246 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.